Review on Pharmacogenomics of ADR

Prof. (Dr.) Mohd Wasiullah; Aman Saroj; Roshan Kumar Yadav; Shashikant Maurya

doi:10.61096/ijamscr.v10.iss3.2022.293-298

Issue

Vol. 10 No. 3 (2022): 2022 Volume -10 - Issue 3

Issue Published : August 15, 2022

Date Log

Submitted

July 8, 2022

Published

July 8, 2022

Review on Pharmacogenomics of ADR

https://doi.org/10.61096/ijamscr.v10.iss3.2022.293-298

Prof. (Dr.) Mohd Wasiullah

Professor& Principal, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttat Pradesh, India

Aman Saroj

Deptartment of Pharmacy, Prasad Institute of Technology, Uttat Pradesh, India

Roshan Kumar Yadav

Deptartment of Pharmacy, Prasad Institute of Technology, Uttat Pradesh, India

Shashikant Maurya

Deptartment of Pharmacy, Prasad Institute of Technology, Uttat Pradesh, India

International Journal of Allied Medical Sciences and Clinical Research, Vol. 10 No. 3 (2022): 2022 Volume -10 - Issue 3
Article Published : July 8, 2022

Abstract

Adverse drug reactions are a leading source of morbidity and mortality in the world.Although many adverse medication reactions are thought to be unpreventable, emerging research suggests that these events could be avoided by tailoring pharmacological regimens based on genetic data.Pharmacogenomics' arrival could usher in a new era of personalised medicine. As a first step in using genetic information to optimise medication therapy, nonpreventable ADRs may become at least partially preventable. This study presents actual evidence that pharmacogenomics could potentially affects adverse drug reactions (ADRs), a serious issue.

Keywords

Pharmacogenomics, Adverse Drug reaction (ADRs), Drug-Drug Interactions (DDI), ADME, Cytochrome P450 (CYP) Enzymes, Single Nucleotide Polymorphism (SNPs), Mutation.

Prof. (Dr.) Mohd Wasiullah, Aman Saroj, Roshan Kumar Yadav, & Shashikant Maurya. (2022). Review on Pharmacogenomics of ADR. International Journal of Allied Medical Sciences and Clinical Research, 10(3), 293–298. https://doi.org/10.61096/ijamscr.v10.iss3.2022.293-298

Download Citation

References

Shoshi A, Hoppe T, Kormeier B, Ogultarhan V, Hofestädt R. GraphSAW: a web-based system for graphical analysis of drug interactions and side effects using pharmaceutical and molecular data. BMC Med Inform Decis Mak. 2015;15:15. doi: 10.1186/s12911-015-0139-5, PMID 25881043.
Rankin A, Cadogan CA, Patterson SM, Kerse N, Cardwell CR, Bradley MC, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2018;9:CD008165. doi: 10.1002/14651858.CD008165.pub4, PMID 30175841.
Latini A, Borgiani P, Novelli G, Ciccacci C. MiRNAs in drug response variability: potential utility as biomarkers for personalized medicine. Pharmacogenomics. 2019;20(14):1049-59. doi: 10.2217/pgs-2019-0089, PMID 31559917.
Beutler E. The hemolytic effect of primaquine and related compounds: a review. Blood. 1959;14(2):103-39. doi: 10.1182/blood.V14.2.103.103, PMID 13618370.
Cha PC, Mushiroda T, Takahashi A, Kubo M, Minami S, Kamatani N, et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet. 2010;19(23):4735-44. doi: 10.1093/hmg/ddq389, PMID 20833655.
Cacabelos R, Tellado I, Cacabelos P. The epigenetic machinery in the life cycle and pharmacoepigenetics. In: Cacabelos R, editor. Pharmacoepigenetics. Academic Press/Elsevier; 2019. doi: 10.1016/B978-0-12-813939- 4.00001-2 (in press).
Cacabelos R, Torrellas C. Pharmacoepigenomics. Med Epigenet. doi: 10.1016/B978-0-12-803239-8.00032-6.
Europharmagenics Database [internet]. Corunna, (ES): EuroEspes Publishing; 2015. Available from: http://www.europharmagenics.com.
Cacabelos R, Cacabelos P, Aliev G. Genomics and pharmacogenomics of antipsychotic drugs. Open J Psychiatry. 2013;3:46-139.
Seripa D, Lozupone M, Stella E, Paroni G, Bisceglia P, La Montagna M, et al. Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know? Expert Opin Drug Saf. 2017;16(12):1373-85. doi: 10.1080/14740338.2017.1389891, PMID 29025271.
Chavan BS, Kaur G, Gupta D, Aneja J. A Prospective Study to Evaluate the Effect of CYP2D6 Polymorphism on plasma level of risperidone and its Metabolite in North Indian Patients with Schizophrenia. Indian J Psychol Med. 2018;40(4):335-42. doi: 10.4103/IJPSYM.IJPSYM_83_18, PMID 30093744.
Moradi-Marjaneh R, Khazaei M, Seifi S, Hassanian SM, Ferns GA, Avan A. Pharmacogenetics of anticancer drug sensitivity and toxicity in colorectal cancer. Curr Pharm Des. 2018;24(23):2710-8. doi: 10.2174/1381612824666180727144535, PMID 30051785.
Abaji R, Ceppi F, Patel S, Gagné V, Xu CJ, Spinella JF, et al. Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing. Pharmacogenomics. 2018;19(15):1181-93. doi: 10.2217/pgs-2018-0093, PMID 30191766.
Cacabelos R, editor. World guide for drug use and pharmacogenomics. Corunna, (ES): EuroEspes Publishing; 2012; *First world guide of pharmacogenomics (3000 pages).
Liu J, Jiang HH, Wu DK, Zhou YX, Ye HM, Li X, et al. Effect of gene polymorphims on the warfarin treatment at initial stage. Pharmacogenomics J. 2017;17(1):47-52. doi: 10.1038/tpj.2015.81, PMID 26644206.
Yang L, Lu YL, Wang HJ, Zhou WH. [Pharmacogenomics study of 620 whole-exome sequencing: focusing on aspirin application]. Zhonghua Er Ke Za Zhi. 2016;54(5):332-6. doi: 10.3760/cma.j.issn.0578-1310.2016.05.005, PMID 27143073.
Vasudeva K, Chaurasia P, Singh S, Munshi A. Genetic signatures in ischemic stroke: focus on aspirin resistance. CNS Neurol Disord Drug Targets. 2017;16(9):974-82. doi: 10.2174/1871527316666171002115633, PMID 28969559.
Richardson M, Kirkham J, Dwan K, Sloan D, Davies G, Jorgensen A. Influence of genetic variants on toxicity to antitubercular agents: a systematic review and meta-analysis [protocol]. Syst Rev. 2017;6(1):142. doi: 10.1186/s13643-017-0533-4, PMID 28701180.
Arruda MB, Campagnari F, de Almeida TB, Couto-Fernandez JC, Tanuri A, Cardoso CC. Single nucleotide polymorphisms in cellular drug transporters are associated with intolerance to antiretroviral therapy in Brazilian HIV-1 positive individuals. PLOS ONE. 2016;11(9):e0163170. doi: 10.1371/journal.pone.0163170, PMID 27648838.
Swart M, Evans J, Skelton M, Castel S, Wiesner L, Smith PJ, et al. An expanded analysis of pharmacogenetics determinants of efavirenz response that includes 3′-UTR single nucleotide polymorphisms among Black South African HIV/AIDS patients. Front Genet. 2015;6:356. doi: 10.3389/fgene.2015.00356, PMID 26779253.
Cacabelos R, Carril JC, Cacabelos P, et al. Pharmacogenomics of Alzheimer’s disease: genetic determinants of phenotypic variation and therapeutic outcome. J Genom Pharmacogenomics. 2016;1(2):151-209.
Marchesi F, Girmenia C, Goffredo BM, Salvatorelli E, Romano A, Mengarelli A, et al. Isavuconazole: case report and pharmacokinetic considerations. Chemotherapy. 2018;63(5):253-6. doi: 10.1159/000494329, PMID 30458443.
Riazi S, Kraeva N, Hopkins PM. Malignant hyperthermia in the post-genomics era: New Perspectives on an Old Concept. Anesthesiology. 2018;128(1):168-80. doi: 10.1097/ALN.0000000000001878. PMID 28902675.
Scherman D, Fetro C. Drug repositioning for rare diseases: knowledge-based success stories. Therapie. 2020;75(2):161-7. doi: 10.1016/j.therap.2020.02.007. PMID 32164975.
Kalman LV, Agúndez J, Appell ML, Black JL, Bell GC, Boukouvala S, et al. Pharmacogenetic allele nomenclature: international workgroup recommendations for test result reporting. Clin Pharmacol Ther. 2016;99(2):172-85. doi: 10.1002/cpt.280, PMID 26479518.
Cha PC, Mushiroda T, Takahashi A, Kubo M, Minami S, Kamatani N, et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet. 2010;19(23):4735-44. doi: 10.1093/hmg/ddq389, PMID 20833655.
Belle DJ, Singh H. Genetic factors in drug metabolism. Am Fam Physician. 2008;77(11):1553-60. PMID 18581835.
Guideline on good pharmacogenomic practice. European Medicines Agency; 2018.

References

Shoshi A, Hoppe T, Kormeier B, Ogultarhan V, Hofestädt R. GraphSAW: a web-based system for graphical analysis of drug interactions and side effects using pharmaceutical and molecular data. BMC Med Inform Decis Mak. 2015;15:15. doi: 10.1186/s12911-015-0139-5, PMID 25881043.

Rankin A, Cadogan CA, Patterson SM, Kerse N, Cardwell CR, Bradley MC, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2018;9:CD008165. doi: 10.1002/14651858.CD008165.pub4, PMID 30175841.

Latini A, Borgiani P, Novelli G, Ciccacci C. MiRNAs in drug response variability: potential utility as biomarkers for personalized medicine. Pharmacogenomics. 2019;20(14):1049-59. doi: 10.2217/pgs-2019-0089, PMID 31559917.

Beutler E. The hemolytic effect of primaquine and related compounds: a review. Blood. 1959;14(2):103-39. doi: 10.1182/blood.V14.2.103.103, PMID 13618370.

Cha PC, Mushiroda T, Takahashi A, Kubo M, Minami S, Kamatani N, et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet. 2010;19(23):4735-44. doi: 10.1093/hmg/ddq389, PMID 20833655.

Cacabelos R, Tellado I, Cacabelos P. The epigenetic machinery in the life cycle and pharmacoepigenetics. In: Cacabelos R, editor. Pharmacoepigenetics. Academic Press/Elsevier; 2019. doi: 10.1016/B978-0-12-813939- 4.00001-2 (in press).

Cacabelos R, Torrellas C. Pharmacoepigenomics. Med Epigenet. doi: 10.1016/B978-0-12-803239-8.00032-6.

Europharmagenics Database [internet]. Corunna, (ES): EuroEspes Publishing; 2015. Available from: http://www.europharmagenics.com.

Cacabelos R, Cacabelos P, Aliev G. Genomics and pharmacogenomics of antipsychotic drugs. Open J Psychiatry. 2013;3:46-139.

Seripa D, Lozupone M, Stella E, Paroni G, Bisceglia P, La Montagna M, et al. Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know? Expert Opin Drug Saf. 2017;16(12):1373-85. doi: 10.1080/14740338.2017.1389891, PMID 29025271.

Chavan BS, Kaur G, Gupta D, Aneja J. A Prospective Study to Evaluate the Effect of CYP2D6 Polymorphism on plasma level of risperidone and its Metabolite in North Indian Patients with Schizophrenia. Indian J Psychol Med. 2018;40(4):335-42. doi: 10.4103/IJPSYM.IJPSYM_83_18, PMID 30093744.

Moradi-Marjaneh R, Khazaei M, Seifi S, Hassanian SM, Ferns GA, Avan A. Pharmacogenetics of anticancer drug sensitivity and toxicity in colorectal cancer. Curr Pharm Des. 2018;24(23):2710-8. doi: 10.2174/1381612824666180727144535, PMID 30051785.

Abaji R, Ceppi F, Patel S, Gagné V, Xu CJ, Spinella JF, et al. Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing. Pharmacogenomics. 2018;19(15):1181-93. doi: 10.2217/pgs-2018-0093, PMID 30191766.

Cacabelos R, editor. World guide for drug use and pharmacogenomics. Corunna, (ES): EuroEspes Publishing; 2012; *First world guide of pharmacogenomics (3000 pages).

Liu J, Jiang HH, Wu DK, Zhou YX, Ye HM, Li X, et al. Effect of gene polymorphims on the warfarin treatment at initial stage. Pharmacogenomics J. 2017;17(1):47-52. doi: 10.1038/tpj.2015.81, PMID 26644206.

Yang L, Lu YL, Wang HJ, Zhou WH. [Pharmacogenomics study of 620 whole-exome sequencing: focusing on aspirin application]. Zhonghua Er Ke Za Zhi. 2016;54(5):332-6. doi: 10.3760/cma.j.issn.0578-1310.2016.05.005, PMID 27143073.

Vasudeva K, Chaurasia P, Singh S, Munshi A. Genetic signatures in ischemic stroke: focus on aspirin resistance. CNS Neurol Disord Drug Targets. 2017;16(9):974-82. doi: 10.2174/1871527316666171002115633, PMID 28969559.

Richardson M, Kirkham J, Dwan K, Sloan D, Davies G, Jorgensen A. Influence of genetic variants on toxicity to antitubercular agents: a systematic review and meta-analysis [protocol]. Syst Rev. 2017;6(1):142. doi: 10.1186/s13643-017-0533-4, PMID 28701180.

Arruda MB, Campagnari F, de Almeida TB, Couto-Fernandez JC, Tanuri A, Cardoso CC. Single nucleotide polymorphisms in cellular drug transporters are associated with intolerance to antiretroviral therapy in Brazilian HIV-1 positive individuals. PLOS ONE. 2016;11(9):e0163170. doi: 10.1371/journal.pone.0163170, PMID 27648838.

Swart M, Evans J, Skelton M, Castel S, Wiesner L, Smith PJ, et al. An expanded analysis of pharmacogenetics determinants of efavirenz response that includes 3′-UTR single nucleotide polymorphisms among Black South African HIV/AIDS patients. Front Genet. 2015;6:356. doi: 10.3389/fgene.2015.00356, PMID 26779253.

Cacabelos R, Carril JC, Cacabelos P, et al. Pharmacogenomics of Alzheimer’s disease: genetic determinants of phenotypic variation and therapeutic outcome. J Genom Pharmacogenomics. 2016;1(2):151-209.

Marchesi F, Girmenia C, Goffredo BM, Salvatorelli E, Romano A, Mengarelli A, et al. Isavuconazole: case report and pharmacokinetic considerations. Chemotherapy. 2018;63(5):253-6. doi: 10.1159/000494329, PMID 30458443.

Riazi S, Kraeva N, Hopkins PM. Malignant hyperthermia in the post-genomics era: New Perspectives on an Old Concept. Anesthesiology. 2018;128(1):168-80. doi: 10.1097/ALN.0000000000001878. PMID 28902675.

Scherman D, Fetro C. Drug repositioning for rare diseases: knowledge-based success stories. Therapie. 2020;75(2):161-7. doi: 10.1016/j.therap.2020.02.007. PMID 32164975.

Kalman LV, Agúndez J, Appell ML, Black JL, Bell GC, Boukouvala S, et al. Pharmacogenetic allele nomenclature: international workgroup recommendations for test result reporting. Clin Pharmacol Ther. 2016;99(2):172-85. doi: 10.1002/cpt.280, PMID 26479518.

Belle DJ, Singh H. Genetic factors in drug metabolism. Am Fam Physician. 2008;77(11):1553-60. PMID 18581835.

Guideline on good pharmacogenomic practice. European Medicines Agency; 2018.

Author biographies is not available.